Exelixis, Inc. (EXEL) CFO Sells $2,679,000.00 in Stock
Exelixis, Inc. (NASDAQ:EXEL) CFO Christopher J. Senner sold 100,000 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $26.79, for a total transaction of $2,679,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Exelixis, Inc. (NASDAQ EXEL) opened at 27.57 on Friday. The firm has a market capitalization of $8.10 billion, a price-to-earnings ratio of 139.24 and a beta of 1.97. Exelixis, Inc. has a 12 month low of $10.04 and a 12 month high of $29.50. The firm’s 50-day moving average is $27.06 and its 200 day moving average is $23.39.
Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.02. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. The firm had revenue of $99.01 million for the quarter, compared to the consensus estimate of $85.27 million. During the same period last year, the firm posted ($0.15) EPS. Exelixis’s quarterly revenue was up 173.1% compared to the same quarter last year. Equities analysts predict that Exelixis, Inc. will post $0.27 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/exelixis-inc-exel-cfo-sells-2679000-00-in-stock/1567841.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in EXEL. BlackRock Inc. raised its holdings in shares of Exelixis by 33,678.5% in the 1st quarter. BlackRock Inc. now owns 19,155,466 shares of the biotechnology company’s stock worth $415,099,000 after purchasing an additional 19,098,757 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Exelixis by 12.8% in the 1st quarter. Vanguard Group Inc. now owns 23,735,071 shares of the biotechnology company’s stock worth $514,339,000 after purchasing an additional 2,696,877 shares in the last quarter. Matrix Capital Management Company LP raised its holdings in shares of Exelixis by 8.8% in the 2nd quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock worth $372,343,000 after purchasing an additional 1,225,000 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of Exelixis in the 2nd quarter worth approximately $28,689,000. Finally, Meditor Group Ltd raised its holdings in shares of Exelixis by 5.5% in the 2nd quarter. Meditor Group Ltd now owns 20,229,713 shares of the biotechnology company’s stock worth $498,258,000 after purchasing an additional 1,046,000 shares in the last quarter. Institutional investors and hedge funds own 79.20% of the company’s stock.
Several equities analysts have issued reports on EXEL shares. BidaskClub upgraded shares of Exelixis from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Cowen and Company restated an “outperform” rating on shares of Exelixis in a research note on Thursday, August 10th. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $28.00 price objective for the company in a research note on Tuesday, July 4th. William Blair restated an “outperform” rating on shares of Exelixis in a research note on Thursday, July 27th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $26.00 target price on shares of Exelixis in a report on Thursday, September 7th. Five equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $26.51.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.